Recipharm Completes Capacity Expansion
Recipharm’s new blow-fill-seal machinery is now operational following a substantial investment last year at its facility in Kaysersberg, France.
The €18 million investment added a new blow-fill-seal, high-speed filling, and packaging line to the site, upping the total number of lines to eight and increasing the facility’s manufacturing capacity by 200 million unidoses per year.
In addition, the investment adds 2,400 square meters to the facility, creating space for three more machines, which will ultimately allow the site to manufacture over 1.2 billion unidoses per year.
Yves Buelens, general manager at Recipharm’s Kaysersberg site, said, “Recipharm has only owned the facility for two years and during that time have taken some very fast and positive decisions to invest in Kaysersberg. We have worked hard to develop a flexible service that can cater for even the most complex of projects. Adding the line to our facility will allow us to take on new customer projects more quickly, as well as continue to meet our current customers’ requirements. The additional space we’ve added also means we are also well positioned for further growth in line with future customer demand.”
The Kaysersberg site specializes in blow-fill-seal technology for sterile liquids. The site manufactures single dose units and has an advanced aseptic process for sterile liquid packaging applications.
Looking for chemical products? Let suppliers reach out to you!
2026-07-14
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
India丨IFC invests Rs 300 crore in Crystal Crop Protection
-
4 Pharma Firms Lose Licenses in Jammu and Kashmir Amid Illegal Drug Sales Crackdown
-
Vertex Shares Plunge 14.4 Percent After Pain Drug Trial Misses Key Target and Study Halt
-
Syndax Q2 Net Loss Widens to $71.8 Million Despite 43 Percent Revenue Surge and New Drug Momentum
-
Sandoz Set to Slash Canadian Weight-loss Drug Prices by Up to 70 Percent Generics Could Expand Patient Access
-
Pfizer Lifts 2025 Profit Forecast After Q2 Earnings Beat Sales Hit $14.65 Billion Shares Jump 2.8 Percent
-
Affordable GLP-1s Could Rewrite the Global Obesity Market
-
A Cold-Chain Crackdown in Delhi Sends a Much Bigger Message
-
China’s Approval of Pfizer’s GLP-1 Drug Signals a Sharper Obesity Race
-
South Africa Wants Lenacapavir at Home, Not Just Imported
Recommend Reading
-
West Asia’s Conflict Is Testing the Hidden Fragility of Pharma Trade
-
₹27,548 Crore Pharma Giant Cipla Enters Weight Management Battle as Obesity Demand Surges
-
60 Percent Workforce Held by Top 10 Firms! China’s TCM Industry Faces Fierce Reshuffle as Private Leaders Expand Fast
-
The Pill That Could Swallow the Needle: Novo Nordisk Launches Oral Wegovy in U.S. Weight-Loss Revolution
-
The $6 Billion Gold Rush: Generic Semaglutide Set to Reshape Global Pharma After Patent Cliff
-
Weak Supply and Demand Weigh Down Melamine Market Sentiment
-
BASF Strengthens Its Liquid Enzyme Portfolio for Laundry and Cleaning Industries
-
September Methanol Market Trends Narrowly Consolidate
-
Supply-demand contradiction of lithium carbonate intertwined, prices fluctuate downward
-
HARKE GROUP Acquires Vendico Group, Strengthening Nordic Market leadership